A subcutaneous infusion pump is a small, programmable device that delivers medication into the fatty tissue just beneath the skin at a controlled, continuous rate. The most familiar version is the insulin pump used by people with diabetes, but the technology has spread well beyond blood sugar management into pain control, palliative care, immunology, and neurology. What ties all these applications together is the same basic advantage: instead of repeated injections that create peaks and valleys of drug concentration, a subcutaneous pump maintains a steadier level of medication in the bloodstream for hours or days at a time.
How the Device Actually Works
At its core, a subcutaneous infusion pump has three parts: a reservoir that holds the drug, a motorized mechanism that pushes the drug out at a set rate, and a thin cannula or needle inserted into the subcutaneous tissue. The cannula typically sits in the abdomen, thigh, or upper arm, held in place by an adhesive patch. The pump’s motor can be programmed to deliver a slow, steady “basal” rate around the clock and, depending on the application, allow the user to trigger extra doses on demand.
For insulin, the pharmacokinetics of continuous subcutaneous infusion turn out to be surprisingly similar to those of a single bolus injection. A study in patients with diabetes found that the absorption rate, elimination rate, and total drug exposure did not differ significantly between the two delivery methods, meaning the pump does not change how the body handles insulin once it arrives under the skin. What the pump changes is timing and control.1PubMed. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients A separate study using insulin aspart confirmed that bioavailability from subcutaneous pump delivery was close to 100 percent, matching both single-shot injection and intravenous infusion.2PubMed. Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery In other words, the drug itself doesn’t behave differently just because a pump delivered it. The value is in the precision of dosing over time.
Insulin Pumps and Closed-Loop Systems
Insulin delivery remains the dominant use case. For people with Type 1 diabetes and some with Type 2, a pump replaces multiple daily injections with a device that can be fine-tuned to match the body’s changing insulin needs throughout the day. The basal rate can be adjusted in tiny increments, and bolus doses can be delivered before meals without reaching for a syringe.
The real frontier here is the closed-loop system, sometimes called an artificial pancreas. These systems pair a subcutaneous insulin pump with a continuous glucose monitor and a software algorithm that adjusts insulin delivery automatically based on real-time glucose readings.3PubMed Central. Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions The person still wears the pump, but the algorithm takes over much of the decision-making, increasing insulin when glucose rises and dialing it back when glucose drops.4Heliyon. An overview of advancements in closed-loop artificial pancreas system Early-generation hybrid closed-loop systems still require the user to announce meals and confirm boluses, but the technology is steadily moving toward full automation.
Patch Pumps Versus Traditional Tubed Pumps
If you picture an insulin pump, you probably imagine a pager-sized box clipped to a belt, connected by thin tubing to a cannula under the skin. That is the traditional “durable” pump. Over the past decade, a second form factor has gained ground: the patch pump, which sticks directly to the body with an adhesive layer and eliminates tubing entirely. Patch pumps tend to be smaller, more discreet, and simpler to use.5PubMed Central. Patch Pumps: Are They All the Same?
The trade-off is precision. A bench study comparing several pumps found meaningful differences in single-dose accuracy. Durable pumps from various manufacturers had a moderate percentage of individual doses falling outside tight accuracy windows, but one patch pump model tested substantially worse. When single doses were averaged over longer windows of 30 minutes to two hours, the durable pumps tightened up considerably while the patch pump still had a significant share of doses outside acceptable thresholds.6PubMed Central. Comparative dose accuracy of durable and patch insulin infusion pumps For basal delivery over hours, these pulse-to-pulse variations smooth out, but for people who rely on precise mealtime boluses, the accuracy gap is worth knowing about. Newer patch pump generations have improved, and the field is evolving quickly, so specific model comparisons date fast.
Subcutaneous Pumps in Pain Management
Outside diabetes, one of the largest applications is patient-controlled subcutaneous analgesia for cancer pain. The concept is the same as an intravenous patient-controlled pump you might encounter in a hospital, but the subcutaneous route lets people use the device at home with a simple cannula in the abdomen or thigh. A randomized trial comparing subcutaneous hydromorphone and morphine for moderate-to-severe cancer pain found both drugs effectively relieved pain, with hydromorphone acting more quickly.7PubMed. Patient Controlled Subcutaneous Analgesia of Hydromorphone Versus Morphine to Treat Moderate and Severe Cancer Pain
A larger observational study of hydromorphone delivered this way showed dramatic improvements across multiple dimensions. Pain scores dropped sharply, sleep quality improved, and anxiety and depression scores fell. The equivalent oral morphine dose the patients needed also dropped substantially, suggesting the continuous subcutaneous route was delivering the drug more efficiently than intermittent oral dosing had been.8Frontiers in Pain Research. Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management Another trial found that sufentanil given subcutaneously at home outperformed morphine on pain scores over two months and caused less nausea and drowsiness.9PubMed Central. Patient‐controlled subcutaneous analgesia using sufentainil or morphine in home care treatment in patients with stage III‐IV cancer
The practical appeal for cancer patients is that home-based subcutaneous pumps avoid the infection risks and logistical burdens of intravenous lines. A nurse can set the device up, the patient can press a button for breakthrough pain, and the continuous background infusion handles baseline pain control without anyone needing to swallow pills on a schedule.
Palliative Care and the Syringe Driver
In British palliative medicine, the subcutaneous infusion pump is often called a “syringe driver.” The device has been a mainstay of end-of-life symptom control since the early 1980s, delivering combinations of opioids, sedatives, and antiemetics under the skin when a dying person can no longer swallow.10PubMed. The syringe driver and the subcutaneous route in palliative care: the inventor, the history and the implications The technology is simple and reliable, which is exactly what you want when the goal shifts from curing disease to keeping someone comfortable.
A mixed-methods study across hospital departments found that roughly seven in ten patients received continuous infusions during their final week of life. But the same study raised a concerning pattern: about one in five patients on continuous infusions had no documented clinical indication for the infusion in their medical records. Staff interviews revealed that continuous infusions had, in some settings, become almost automatic for patients labeled “palliative,” driven partly by workflow convenience rather than individualized symptom assessment.11PubMed Central. “Palliative Syringe Driver”? A Mixed-Methods Study in Different Hospital Departments on Continuous Infusions of Sedatives and/or Opioids in End-of-Life Care The syringe driver is a genuinely useful tool, but its association with dying has made it emotionally loaded for families and, according to the study’s interviewees, sometimes leads to reflexive rather than thoughtful prescribing.
Elastomeric pumps offer an alternative for palliative patients being discharged home. These are disposable, non-electronic devices: a balloon-like reservoir filled with medication that deflates slowly, pushing the drug through tubing at a preset rate. One hospital program successfully used elastomeric pumps for over 100 patient discharges, saving significant costs compared with keeping those patients in hospital beds.12PubMed Central. Elastomeric Pumps for Continuous Subcutaneous Infusion of Symptom Control Medication on Discharge Because the pumps have no electronics, they require no programming and no batteries, making them practical for home use by non-specialists.
Immunoglobulin Replacement Therapy
People with primary immunodeficiency disorders need regular infusions of immunoglobulin to compensate for an immune system that does not produce enough antibodies on its own. Traditionally, this meant monthly intravenous infusions in a clinic, each lasting several hours. Subcutaneous immunoglobulin delivery using a small pump or manual “push” syringe lets patients self-administer at home on a weekly or biweekly schedule.
A retrospective review of patients switched to subcutaneous push delivery found that it maintained adequate immunoglobulin levels in treatment-naïve patients and actually produced higher steady-state levels than previous intravenous therapy in patients who switched. Antibiotic prescriptions dropped in the naïve group, and hospitalization rates stayed similar, suggesting the at-home subcutaneous approach was at least as effective as clinic-based intravenous infusions.13PubMed Central. Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba For patients who previously spent a full day every month in an infusion chair, the shift to home subcutaneous delivery is a quality-of-life transformation.
Parkinson’s Disease and Continuous Dopaminergic Stimulation
As Parkinson’s disease progresses, oral medications begin to wear off unpredictably, leaving patients oscillating between “on” periods with reasonable movement and “off” periods of stiffness and immobility. Continuous subcutaneous infusion of dopaminergic drugs aims to flatten those swings.
Apomorphine, a potent dopamine agonist, has been delivered by subcutaneous pump for years in Europe and more recently in the United States. In a phase 3 U.S. trial, continuous subcutaneous apomorphine infusion reduced off time by about three hours per day on average, with a corresponding increase of roughly three hours of good on time by 12 weeks of maintenance treatment.14PubMed Central. Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations Newer levodopa-based subcutaneous formulations, such as foslevodopa/foscarbidopa, have shown similar benefits in randomized trials and represent the first approved levodopa product designed for continuous subcutaneous delivery.15PubMed. Continuous subcutaneous infusion therapies in Parkinson’s disease: evidence of efficacy and safety For patients who are not candidates for intestinal gel pumps or deep brain stimulation, subcutaneous infusion offers a less invasive middle ground.
What Happens at the Infusion Site
Any device that parks a foreign object under your skin for days at a time will provoke a tissue response. A systematic study comparing steel and Teflon infusion cannulas in a live model found that neither material was clearly superior in terms of tissue inflammation. Both triggered increasing expression of inflammatory markers by seven days of wear. Steel cannulas, being rigid with a sharp tip, caused more bleeding in the first few days, but the flexible Teflon cannulas did not score better on overall tissue histology.16PubMed Central. Systematic in vivo evaluation of the time-dependent inflammatory response to steel and Teflon insulin infusion catheters This is one reason pump users are advised to rotate their infusion sites every two to three days.
Over months and years of repeated use, a more stubborn problem can develop: lipohypertrophy, which is a buildup of abnormal fatty tissue at frequently used injection or infusion sites. An ultrasound screening study of adults with Type 1 diabetes found that all examined injection sites showed areas of increased tissue density compared with surrounding normal tissue. About 70 percent of participants had measurably thicker skin layers at their usual sites, and the depth of the fatty nodules closely correlated with needle length.17BMJ Open Diabetes Research & Care. Characteristics and morphology of lipohypertrophic lesions in adults with type 1 diabetes with ultrasound screening These lumps are not just cosmetic. Insulin absorbed through lipohypertrophic tissue is erratic, making blood sugar control harder. The main risk factors are predictable: longer duration of insulin treatment, not rotating sites, reusing needles, and more injections per day.18PubMed. Insulin-related lipohypertrophy: ultrasound characteristics, risk factors, and impact of glucose fluctuations
Infection is another concern, particularly for pump cannulas left in place for multiple days. Researchers have developed antimicrobial-coated cannulas that prevented biofilm formation from drug-resistant organisms for up to two weeks in lab testing, far exceeding the typical two-to-three-day set change schedule.19PubMed Central. Development of Gendine-Coated Cannula for Continuous Subcutaneous Insulin Infusion for Extended Use If these coatings prove out clinically, they could allow longer wear times and reduce both infection rates and the hassle of frequent site changes.
When the Pump Fails to Deliver
One underappreciated risk is occlusion, where the infusion line gets blocked and insulin or other medication stops flowing. The pump eventually detects the pressure buildup and alarms, but how long that takes varies enormously. A bench study of ten pump systems found that at a standard adult basal rate, all pumps detected an occlusion within five hours. But at a low basal rate typical for a child, nine of the ten systems took longer than six to eight hours to alarm, with some exceeding 40 hours.20PubMed Central. Occlusion Detection Time in Insulin Pumps at Two Different Basal Rates For a child on a very low background rate, that means the pump could be delivering nothing for an entire day before anyone is alerted. This is one reason pediatric endocrinologists emphasize frequent blood glucose checks even with pump therapy, and why closed-loop systems that detect rising glucose from sensor data offer an extra safety layer beyond the pump’s own mechanical alarms.
Expanding What the Subcutaneous Space Can Absorb
A fundamental limitation of subcutaneous delivery is volume. The tissue under the skin has a structure built from hyaluronan and collagen fibers that resists large fluid injections, which is why a typical subcutaneous injection tops out at one or two milliliters before it gets uncomfortable or fails to absorb properly. This matters when drugs are formulated at low concentrations and require large volumes to deliver a therapeutic dose.
A recombinant human hyaluronidase enzyme has been developed to get around this. It temporarily breaks down hyaluronan in the tissue, opening channels that allow larger volumes to disperse and absorb.21PubMed. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration Co-formulated with drugs that would otherwise need intravenous infusion, this enzyme has enabled subcutaneous versions of several biologics, cutting administration time from hours to minutes and shifting treatment from infusion clinics to home settings.22PubMed Central. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20 The hyaluronan regenerates within about 24 to 48 hours, so the tissue returns to its normal state between doses. This technology has already reached the market in combination with drugs like rituximab and trastuzumab, which are monoclonal antibodies for cancer treatment that previously required lengthy IV infusions.
Implantable and Nanofluidic Devices
Beyond wearable pumps, researchers are developing fully implantable subcutaneous delivery systems. In one line of work, a nanochannel delivery implant placed under the skin of rhesus macaques sustained release of two HIV prevention drugs for 83 days, reaching protective blood levels within three days of implantation. Unlike conventional implants that run out and must be replaced, this device incorporates ports that allow transcutaneous refilling through the skin with a needle, extending its lifespan indefinitely.23PubMed Central. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis A follow-up study used the same platform to deliver islatravir, another HIV prevention drug, and demonstrated protection against simian HIV infection in primates.24PubMed. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates
These are still preclinical devices, but they represent a shift in what “subcutaneous infusion” might mean in the future. Instead of wearing a pump that must be programmed and recharged, a person could have a small implant topped up periodically at a clinic visit, delivering drug at a constant rate between refills. For conditions requiring long-term prophylaxis or chronic disease management, the appeal is obvious: no daily pills, no weekly injections, no external device to manage.
Subcutaneous Pumps in Veterinary Medicine and Research
Animals benefit from continuous subcutaneous delivery for many of the same reasons humans do: steady drug levels, less handling stress, and fewer injections. Osmotic pumps, tiny capsule-shaped devices implanted under the skin, are widely used in preclinical research to deliver investigational drugs at a constant rate without any researcher intervention after implantation. They eliminate the need for repeated dosing and avoid the blood-level swings that come with intermittent injections, making them particularly useful for evaluating drugs where steady-state concentrations matter.25PubMed. Long-Term Constant Subcutaneous Drug Administration
Clinical veterinary medicine has been slower to adopt electronic pumps. A pilot study testing an implantable insulin pump in healthy cats found that while the animals tolerated the device well, four of ten pumps failed for technical reasons and one cat developed life-threatening low blood sugar from insulin leakage. The researchers concluded that the hardware needs further development before clinical use.26PubMed. Use of an implantable pump for controlled subcutaneous insulin delivery in healthy cats Hydromorphone, meanwhile, is increasingly popular as a veterinary pain medication delivered subcutaneously, though typically by intermittent injection rather than pump.27European Journal of Pain Supplements. Analgesic applications for a subcutaneous implant that continuously releases hydromorphone The gap between research-grade osmotic pumps and reliable clinical-grade implantable pumps for companion animals remains wide.
Design Challenges That Still Matter
Wearable subcutaneous delivery devices face a set of engineering problems that might seem trivial until you live with one attached to your body every day. Fluid dynamics at very low flow rates create accuracy problems, since a pump pushing a fraction of a microliter per pulse must contend with surface tension, air bubbles, and tissue back-pressure. Tissue resistance varies between people and even between sites on the same person, affecting how quickly drug disperses. Human factors are equally important: a device that is difficult to fill, confusing to program, or uncomfortable to wear will eventually end up in a drawer regardless of how well it works pharmacologically.28Biomedical Materials & Devices. Wearable Devices for Subcutaneous Delivery of Large-Volume Biologics: Design, Use, and Regulatory Perspective
Researchers have explored alternatives to traditional electromechanical motors. One group built a wearable pump driven by a piezoelectric element, a material that flexes when voltage is applied. Their prototype achieved precise flow control down to fractions of a microliter per pulse.29Sensors and Actuators A: Physical. A wearable insulin delivery system based on a piezoelectric micropump Whether piezoelectric, shape-memory alloy, or electroosmotic pumping mechanisms will eventually replace the small stepper motors in current devices remains an open question, but the motivation is clear: smaller, quieter, more efficient, and more accurate.
Environmental sustainability is also starting to enter the conversation. Disposable infusion sets, single-use reservoirs, adhesive patches, and patch pumps designed for three-day use generate a continuous stream of medical waste. As the number of people using wearable delivery devices grows across diabetes, immunology, and oncology, the cumulative environmental footprint is becoming harder to ignore. Regulatory agencies are beginning to factor sustainability into device approval frameworks, though how that will reshape product design in practice remains to be seen.